Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04176380 · ClinicalTrials.gov registry record · Phase 2
RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma
A Phase 2 study, sponsored by Rapa Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT04176380: Completed Phase 2 study, sponsored by Rapa Therapeutics.
NCT04176380 is a Phase 2 study that has completed, run by Rapa Therapeutics. The registered enrollment target is 15 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04176380, a Phase 2 study, has completed, sponsored by Rapa Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
RAPA-201-RRMM is an open-label, single-arm, non-randomized multicenter phase II study of RAPA-201 autologous T cells in adults with relapsed, refractory multiple myeloma who have received at least three (3) prior lines.
Primary Outcome
To determine the overall response rate, as evaluated by IMWG criteria, in patients with relapse, refractory multiple myeloma (RRMM) treated with autologous RAPA-201 cells and a pentostatin-cyclophosphamide (PC) host conditioning regimen.
Interventions
- BIOLOGICAL RAPA-201 Autologous T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-12-02 |
| Est. Completion | 2023-06-06 |
| Phase | Phase 2 |
What the finished NCT04176380 record still lists
NCT04176380 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which RAPA-201 Autologous T cells is the first listed.
NCT04176380 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04176380 about?
NCT04176380 is a clinical study titled "RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma". RAPA-201-RRMM is an open-label, single-arm, non-randomized multicenter phase II study of RAPA-201 autologous T cells in adults with relapsed, refractory multiple myeloma who have received at least three (3) prior lines.
What is the current status of trial NCT04176380?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2020-12-02. Estimated completion is 2023-06-06.
What interventions are being tested in trial NCT04176380?
The interventions under investigation include: RAPA-201 Autologous T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT04176380?
This trial is sponsored by Rapa Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04176380's enrollment target sits among peer trials
15 1919th of 2000 higher than 60 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI